Ildong Pharmaceutical (249420) Fundamentals 2026 — P/E 11.9x, Revenue Analysis | SniperIQ
Ildong Pharmaceutical (249420) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩423.8B, trading at ₩13450.00 on the KSC. This SniperIQ fundamentals page covers Ildong Pharmaceutical's valuation (P/E 11.9x, P/B 1.5x), profitability (net margin 6.1%), revenue (₩566.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ildong Pharmaceutical's market cap?
Ildong Pharmaceutical (249420) has a market capitalization of approximately ₩423.8B, trading at ₩13450.00 on the KSC. Market cap moves with the live share price.
What is Ildong Pharmaceutical's P/E ratio?
Ildong Pharmaceutical's trailing twelve-month P/E ratio is 11.9x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ildong Pharmaceutical?
Ildong Pharmaceutical runs a net profit margin of 6.1%, a gross margin of 38.7%, and an operating margin of 3.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ildong Pharmaceutical generate?
Ildong Pharmaceutical reported revenue of ₩566.9B for fiscal year 2025, with net income of ₩27.7B and earnings per share (EPS) of 942.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ildong Pharmaceutical pay a dividend?
Ildong Pharmaceutical offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ildong Pharmaceutical financially healthy?
Ildong Pharmaceutical carries a debt-to-equity ratio of 0.54x and a current ratio of 0.99x, with a market beta of 0.84. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ildong Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ildong Pharmaceutical (249420) the key facts are: market cap ₩423.8B, P/E 11.9x, revenue ₩566.9B, 52-week range 13150-45050. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ildong Pharmaceutical's full fundamentals live
Get Ildong Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.